BACKGROUND: The indications for bevacizumab (a vascular endothelial growth factor inhibitor) have been expanded recently. Despite concerns for cerebrovascular events from bevacizumab treatment, detailed clinical and radiologic information are lacking. METHODS: Using the Mayo Clinic Rochester database (January 2006-September 2010), we identified bevacizumab-treated patients who developed intracerebral hemorrhage, ischemic stroke or transient ischemic attack within 3 weeks of bevacizumab treatment. Functional recovery was assessed using the modified Rankin scale 3 months following the onset of cerebrovascular events. RESULTS: Ten consecutive patients (median age 58 years, range 37-86) were included in this study. These patients received bevacizumab for a median duration of 3 months (range 2-4 months) for cancer treatment, and developed cerebrovascular events that comprised intratumoral hemorrhage (n = 7), cerebral watershed infarction (n = 1), transient ischemic attack (n = 1), and left vertebral artery occlusion (n = 1). Seven patients had chronic hypertension which was adequately controlled with a single anti-hypertensive agent. Significant increase in blood pressure was observed in nine patients during their acute presentation as compared with their baseline outpatient readings. Six patients died within 3 months of these cerebrovascular events, and the remaining four patients had modest functional recovery. CONCLUSIONS: Cerebrovascular events are early and serious complications that should be considered in bevacizumab-treated patients who present with an acute neurologic deterioration.
BACKGROUND: The indications for bevacizumab (a vascular endothelial growth factor inhibitor) have been expanded recently. Despite concerns for cerebrovascular events from bevacizumab treatment, detailed clinical and radiologic information are lacking. METHODS: Using the Mayo Clinic Rochester database (January 2006-September 2010), we identified bevacizumab-treated patients who developed intracerebral hemorrhage, ischemic stroke or transient ischemic attack within 3 weeks of bevacizumab treatment. Functional recovery was assessed using the modified Rankin scale 3 months following the onset of cerebrovascular events. RESULTS: Ten consecutive patients (median age 58 years, range 37-86) were included in this study. These patients received bevacizumab for a median duration of 3 months (range 2-4 months) for cancer treatment, and developed cerebrovascular events that comprised intratumoral hemorrhage (n = 7), cerebral watershed infarction (n = 1), transient ischemic attack (n = 1), and left vertebral artery occlusion (n = 1). Seven patients had chronic hypertension which was adequately controlled with a single anti-hypertensive agent. Significant increase in blood pressure was observed in nine patients during their acute presentation as compared with their baseline outpatient readings. Six patients died within 3 months of these cerebrovascular events, and the remaining four patients had modest functional recovery. CONCLUSIONS: Cerebrovascular events are early and serious complications that should be considered in bevacizumab-treated patients who present with an acute neurologic deterioration.
Authors: Betty Y Y Tam; Kevin Wei; John S Rudge; Jana Hoffman; Joceyln Holash; Sang-ki Park; Jenny Yuan; Colleen Hefner; Cecile Chartier; Jeng-Shin Lee; Shelly Jiang; Nihar R Nayak; Nihar R Niyak; Frans A Kuypers; Lisa Ma; Uma Sundram; Grace Wu; Joseph A Garcia; Stanley L Schrier; Jacquelyn J Maher; Randall S Johnson; George D Yancopoulos; Richard C Mulligan; Calvin J Kuo Journal: Nat Med Date: 2006-06-25 Impact factor: 53.440
Authors: Balveen Kaur; Fatima W Khwaja; Eric A Severson; Shannon L Matheny; Daniel J Brat; Erwin G Van Meir Journal: Neuro Oncol Date: 2005-04 Impact factor: 12.300
Authors: Mark A Socinski; Corey J Langer; Jane E Huang; Margaret M Kolb; Peter Compton; Lisa Wang; Wallace Akerley Journal: J Clin Oncol Date: 2009-09-08 Impact factor: 44.544
Authors: Johannes Rieger; Oliver Bähr; Klaus Müller; Kea Franz; Joachim Steinbach; Elke Hattingen Journal: J Neurooncol Date: 2009-12-25 Impact factor: 4.130
Authors: L V Klotz; M E Eichhorn; B Schwarz; H Seeliger; M K Angele; K-W Jauch; Christiane J Bruns Journal: Langenbecks Arch Surg Date: 2012-03-14 Impact factor: 3.445
Authors: Deborah T Blumenthal; Orna Aisenstein; Idan Ben-Horin; Dafna Ben Bashat; Moran Artzi; Benjamin W Corn; Andrew A Kanner; Zvi Ram; Felix Bokstein Journal: J Neurooncol Date: 2015-05-05 Impact factor: 4.130